Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Dynasty Wealth Management LLC Purchases New Position in Ionis Pharmaceuticals, Inc. $IONS
05:48am, Wednesday, 21'st Jan 2026
Dynasty Wealth Management LLC acquired a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) during the third quarter, according to the company in its most recent 13F filing with the
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Kyle Jenne Sells 1,823 Shares
05:08am, Wednesday, 21'st Jan 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Kyle Jenne sold 1,823 shares of the business's stock in a transaction that occurred on Friday, January 16th. The shares were sold at an
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Holly Kordasiewicz Sells 4,141 Shares
05:08am, Wednesday, 21'st Jan 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Holly Kordasiewicz sold 4,141 shares of the firm's stock in a transaction that occurred on Friday, January 16th. The stock was sold at
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 8,353 Shares of Stock
05:08am, Wednesday, 21'st Jan 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Shannon Devers sold 8,353 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $7
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Eugene Schneider Sells 9,302 Shares of Stock
05:08am, Wednesday, 21'st Jan 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Eugene Schneider sold 9,302 shares of the stock in a transaction on Friday, January 16th. The stock was sold at an average price of $75
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Brian Birchler Sells 8,480 Shares of Stock
05:08am, Wednesday, 21'st Jan 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Brian Birchler sold 8,480 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, January 16th. The stock was sold at an a
Ionis Pharmaceuticals (NASDAQ:IONS) EVP C Frank Bennett Sells 8,977 Shares of Stock
05:08am, Wednesday, 21'st Jan 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP C Frank Bennett sold 8,977 shares of the firm's stock in a transaction that occurred on Friday, January 16th. The stock was sold at an
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Patrick O’neil Sells 9,191 Shares
05:08am, Wednesday, 21'st Jan 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Patrick O'neil sold 9,191 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, January 16th. The stock was sold at an a
Ionis: Expected 2026 Launch Of Olezarsen In SHTG To Spur Leap In Revenue Growth
11:09am, Tuesday, 20'th Jan 2026
Ionis Pharmaceuticals (IONS) has appreciated ~25% since my last upgrade, reflecting strong momentum. This article spotlights Olezarsen, Ionis's wholly owned molecule, as a key driver of future upside.
Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:16pm, Tuesday, 13'th Jan 2026
Ionis Pharmaceuticals, Inc. (IONS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
National Bank of Canada Sees Significant Reduction in Tweedy Browne International Value's Portfolio
12:02pm, Monday, 12'th Jan 2026
Insights from the Fourth Quarter 2025 N-PORT Filing Tweedy Browne International Value (Trades, Portfolio) recently submitted its N-PORT filing for the fourth q
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced highlights from the Company's 2025 achievements and provided additional updates on key milestones expected
GSK/Ionis Partnered Investigational Drug Shows Strong Results In Large Hepatitis B Studies
11:48am, Wednesday, 07'th Jan 2026
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) partner GSK Plc (NYSE: GSK) on Wednesday shared data from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, of bepirovirsen, an investigational antisense ol
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safet
Ionis to present at 44th Annual J.P. Morgan Healthcare Conference
07:05am, Tuesday, 06'th Jan 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P. Monia, Ph.D., chief executive officer, will present a company overview at the 44th Annual J.
